Wealthspire Advisors (New York)’s Galectin Therapeutics GALT Stock Holding History

Wealthspire Advisors (New York)’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.35M	Hold	721,788	–	–	0.02%	328
2026 Q1	$2.01M	Buy	721,788 +119,815	+20%	+$364K	0.02%	287
2025 Q4	$2.5M	Buy	601,973 +122,455	+26%	+$645K	0.02%	263
2025 Q3	$2.03M	Hold	479,518	–	–	0.01%	277
2025 Q2	$1.01M	Buy	479,518 +81,144	+20%	+$121K	0.01%	383
2025 Q1	$486K	Hold	398,374	–	–	﹤0.01%	521
2024 Q4	$514K	Hold	398,374	–	–	0.01%	506
2024 Q3	$1.1M	Hold	398,374	–	–	0.01%	357
2024 Q2	$900K	Hold	398,374	–	–	0.01%	328
2024 Q1	$952K	Buy	398,374 +214,512	+117%	+$406K	0.01%	325
2023 Q4	$305K	Hold	183,862	–	–	﹤0.01%	519
2023 Q3	$353K	Hold	183,862	–	–	0.01%	458
2023 Q2	$265K	Hold	183,862	–	–	﹤0.01%	476
2023 Q1	$386K	Buy	+183,862	New	+$297K	0.01%	395
2022 Q4	–	Sell	-17,355	Closed	-$28K	–	591
2022 Q3	$28K	Hold	17,355	–	–	﹤0.01%	504
2022 Q2	$23K	Hold	17,355	–	–	﹤0.01%	493
2022 Q1	$28K	Buy	17,355 +3,500	+25%	+$6.77K	﹤0.01%	427
2021 Q4	$29K	Hold	13,855	–	–	﹤0.01%	534
2021 Q3	$54K	Hold	13,855	–	–	﹤0.01%	573
2021 Q2	$44K	Hold	13,855	–	–	﹤0.01%	366
2021 Q1	$30K	Hold	13,855	–	–	﹤0.01%	702
2020 Q4	$31K	Hold	13,855	–	–	﹤0.01%	579
2020 Q3	$37K	Hold	13,855	–	–	﹤0.01%	327
2020 Q2	$42K	Hold	13,855	–	–	﹤0.01%	278
2020 Q1	$27K	Hold	13,855	–	–	﹤0.01%	552
2019 Q4	$40K	Hold	13,855	–	–	﹤0.01%	213
2019 Q3	$51K	Buy	+13,855	New	+$50.1K	﹤0.01%	165

Other funds holding GALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wealthspire Advisors (New York)'s GALT Position: Q2 2026 in Review

Wealthspire Advisors (New York) held its Galectin Therapeutics (GALT) position steady in Q2 2026 at 721,788 shares worth $3.35M. The position accounts for 0.02% of the portfolio, ranked #328.

Wealthspire Advisors (New York) first reported a position in GALT in Q3 2019 and has held it in 27 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

Wealthspire Advisors (New York) held 721,788 shares of Galectin Therapeutics worth $3.35M as of Q2 2026.
Wealthspire Advisors (New York) left its Galectin Therapeutics share count unchanged in Q2 2026.
Galectin Therapeutics made up 0.02% of Wealthspire Advisors (New York)'s portfolio in Q2 2026, its #328 holding.
Wealthspire Advisors (New York) first reported a position in Galectin Therapeutics in Q3 2019 and has held it in 27 quarters since.
98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Wealthspire Advisors (New York)'s 13F filing for Q2 2026, filed 11 Aug 2026.